Two Sigma Advisers
DMRA

Two Sigma Advisers’s Damora Therapeutics DMRA Stock Holding History

Two Sigma Advisers’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,956
Closed -$123K – 2462
2023
Q2 		$123K Sell
1,956
-188
-9% -$10.2K ﹤0.01% 2186
2023
Q1 		$107K Sell
2,144
-360
-14% -$19K ﹤0.01% 2374
2022
Q4 		$72K Sell
2,504
-1,176
-32% -$48.8K ﹤0.01% 2330
2022
Q3 		$174K Sell
3,680
-516
-12% -$26.2K ﹤0.01% 2232
2022
Q2 		$181K Sell
4,196
-1,552
-27% -$71.2K ﹤0.01% 2300
2022
Q1 		$316K Sell
5,748
-5,608
-49% -$315K ﹤0.01% 2197
2021
Q4 		$860K Buy
11,356
+1,616
+17% +$127K ﹤0.01% 1636
2021
Q3 		$874K Buy
+9,740
New +$1.04M ﹤0.01% 1679

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers's DMRA Position: Q3 2023 in Review

Two Sigma Advisers sold out of Damora Therapeutics (DMRA) in Q3 2023, closing a stake of 1,956 shares — an estimated $123K sold.

Two Sigma Advisers first reported a position in DMRA in Q3 2021 and held it in 8 quarters. The position peaked at $874K in Q3 2021. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

  • Two Sigma Advisers reported no remaining Damora Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 1,956 Damora Therapeutics shares in Q3 2023, an estimated $123K.
  • Two Sigma Advisers first reported a position in Damora Therapeutics in Q3 2021 and held it in 8 quarters.
  • Two Sigma Advisers's Damora Therapeutics position peaked at $874K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.